With respect to primary and secondary SS, there was no significant difference between the two groups in the positive rate of the auxiliary investigations except for the slightly higher rate of Anti-Ro/SSA antibodies (100.0% vs. 85.0%) in primary SS (Table 2). This evidence concerns the gene TRIM21 and synovial sarcoma.